Story perspectives

Incyte Buys Vega for $1.25 B, Targeting Von Willebrand Drug

6/9/2026

Summary

Incyte Acquires Vega

Incyte announced a $1.25 billion acquisition of Vega Therapeutics for the von Willebrand disease candidate VGA039.
The deal is Incyte’s first under new CEO Bill Meury, who succeeded Hervé Hoppenot last year.
Executives said VGA039 offers a less burdensome dosing regimen for severe von Willebrand disease patients.
Meury cited strong data, clear regulatory path, commercial opportunity and hematology fit as reasons for the purchase.

Summary

Incyte Gains FDA

VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. FDA.
The transaction, funded by Incyte’s $4 billion cash, must clear a Hart-Scott-Rodino antitrust review and waiting period before closing in Q3 2026.
Lazard, Evercore, Morgan Stanley, Goodwin Procter, and Fenwick & West provide financial and legal advisory services for the deal.
The Phase 3 VIVID-6 study (NCT07115004) will enroll von Willebrand disease patients and deliver results in 2029.

Summary

Incyte Prices VGA039

Incyte Executive Vice President Dave Gardner says VGA039’s annual price is projected at about $500,000.
Truist analyst Srikripa Deverakonda forecasts VGA039 could generate $1 billion in peak sales by 2036, with revenue starting in 2030.
Incyte cites the need to offset expected revenue loss from Jakafi, which posted $3.09 billion in 2025 sales and faces patent expiry around 2028.

History

Historical Context

Pfizer’s 2002 $64.3 billion purchase of Pharmacia marked the era’s biggest biotech-pharma merger, launching a wave of consolidation focused on niche therapies. The strategy continued with later rare-disease buys such as the 2022 $5.4 billion acquisition of Global Blood Therapeutics, and underline pharma’s focus on bleeding-disorder portfolios.

1 of 4

Incyte Acquires Vega

Incyte announced a $1.25 billion acquisition of Vega Therapeutics for the von Willebrand disease candidate VGA039.
The deal is Incyte’s first under new CEO Bill Meury, who succeeded Hervé Hoppenot last year.
Executives said VGA039 offers a less burdensome dosing regimen for severe von Willebrand disease patients.
Meury cited strong data, clear regulatory path, commercial opportunity and hematology fit as reasons for the purchase.

1 / 4